ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · IEX Real-Time Price · USD
5.25
+0.41 (8.47%)
Aug 11, 2022 4:00 PM EDT - Market closed
8.47%
Market Cap 130.39M
Revenue (ttm) 15.37M
Net Income (ttm) -13.26M
Shares Out 24.84M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,486
Open 4.81
Previous Close 4.84
Day's Range 4.81 - 5.25
52-Week Range 3.51 - 8.10
Beta 0.13
Analysts Buy
Price Target 12.24 (+133.1%)
Earnings Date Sep 7, 2022

About IPA

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; c... [Read more...]

Industry Biotechnology
IPO Date Jan 3, 2017
Employees 85
Stock Exchange NASDAQ
Ticker Symbol IPA
Full Company Profile

Financial Performance

In 2022, IPA's revenue was 19.36 million, an increase of 8.11% compared to the previous year's 17.91 million. Losses were -16.71 million, 127.6% more than in 2021.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for IPA stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 133.14% from the latest price.

Price Target
$12.24
(133.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology compa...

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 2...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology compa...

Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analy...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology compa...

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

DIEPENBEEK, Belgium--(BUSINESS WIRE)---- $IPA #AI--Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA's subsidiary Biostrand, a Bel...

IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Cur...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data...

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intellig...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previous...

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics an...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #DHA--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has entered into a defini...

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #DHA--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discover...

Immunoprecise, Elektrofi To Pursue Low-Volume Injectable Formulation Of IPA's COVID-19 Antibody Cocktail

Elektrofi and Immunoprecise Antibodies Ltd (NASDAQ: IPA) have collaborated to explore a high-concentration formulation of IPA's COVID-19 antibody cocktail, PolyTope TATX-03.  The collaboration aims to g...

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contr...

BOSTON--(BUSINESS WIRE)---- $IPA #DHA--Elektrofi (ELEKTROFI, INC) & IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA) (TSXV: IPA) today announced they are entering into a collaboration to explore a high...

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”) (NASDAQ: IPA) (TSXV: IPA) is pleased to report on the latest progress in the devel...

ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wed...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...

ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron

Immunoprecise Antibodies Ltd IPA has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towa...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce the release of data demonstrating...

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Ope...

VICTORIA, British Columbia & OSS, Netherlands--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the relocat...

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody disco...

ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collabo...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSX VENTURE: IPA) and ChemPartner Biologics Co. Ltd. (“ChemPartn...

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...

ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is providing an update on its Polytope™ Develo...

ImmunoPrecise to Present at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference on Thursda...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is presenting at the Benchmark Company's Disco...

IPA Announces Resignation of Director

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member o...

ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

VICTORIA, British Columbia & CASTRES, France--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmac...

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...

ImmunoPrecise's Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...